TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
Status:
Terminated
Trial end date:
2018-08-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in
improving the average daily protein adequacy received through enteral nutrition in
critically-ill participants developing EFI.